01/10/2014 08:21:46 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
09/29/20146:52PMBWMSD stellt erste Ergebnisse zum Prüfgebrauch von Pembrolizumab bei Patienten mit fortgeschrittenem Blasenkrebs auf der ESMO ...
Pembrolizumab-Monotherapie erzielt Gesamtansprechen von 24 Prozent bei Patienten mit PD-L1-positivem fortgeschrittenem Blasenkrebs (Urothelkarzinom) Geplante Phase-3-Studie zu fortgeschrittenem Blasenkrebs soll Ende 2014 eingeleitet werden MSD, in den USA und Kanada als Merck firmierend, meldete heute die erstmalige Präsentation... More...>>
09/29/20145:56PMDJNDoctor Group Backs Implantable Devices to Prevent Teen Pregnancies
By Jeanne Whalen Doctors prescribing contraception to teenage girls who are sexually active should recommend long-acting, implantable devices as a first choice due to their high efficacy rates, the American Academy of Pediatrics said in an updated policy statement. The AAP also backed abstinence counseling, saying "adolescents... More...>>
09/29/20148:25AMBWMSD annuncia la presentazione dei primi dati sull'uso sperimentale di pembrolizumab in pazienti affetti da tumore vescicale a...
Pembrolizumab in monoterapia ha raggiunto un tasso di risposta globale pari al 24% in pazienti affetti da tumore vescicale (uroteliale) avanzato positivo PD-L1 L'avvio dello studio di Fase 3 sul tumore vescicale avanzato è pianificato per la fine del 2014 MSD, nota come Merck negli Stati Uniti e in Canada, oggi ha reso... More...>>
09/29/20146:48AMBWMSD annonce la première présentation des résultats préliminaires sur l’usage expérimental de Pembrolizumab chez des pa...
Pembrolizumab en monothérapie atteint un taux de réponse globale de 24 % chez les patients souffrant d’un cancer avancé de la vessie (urothélial) avec une PD-L1 positive Une étude de phase 3 sur le cancer avancé de la vessie est prévue pour la fin de l’année 2014 MSD, plus connu sous le nom de Merck aux États-Unis... More...>>
09/29/20145:00AMBWMerck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Ad...
KEYTRUDA® monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation... More...>>
09/29/20145:00AMBWMSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder ...
Pembrolizumab monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 MSD, known as Merck in the United States and Canada, today announced the first presentation of data... More...>>
09/28/20145:39AMBWMSD annonce la première présentation, à l’occasion du congrès 2014 de l’ESMO, de résultats concernant l'utilisation ...
Le pembrolizumab administré en monothérapie est parvenu à un taux de réponse globale de 31 pour cent chez des patients atteints d’un cancer de l’estomac avancé PD-L1-positif Une étude de phase 2 débutera au premier trimestre 2015 (KEYNOTE-059) MSD, société connue sous le nom de Merck aux États-Unis et au... More...>>
09/28/20143:15AMBWMerck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced...
KEYTRUDA® monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational... More...>>
09/28/20143:15AMBWMSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer...
Pembrolizumab monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) MSD, known as Merck in the United States and Canada, today announced the first presentation of data on the investigational use... More...>>
09/28/20143:15AMBWMSD annuncia la prima presentazione di dati sull'uso sperimentale di pembrolizumab in pazienti affetti da carcinoma gastrico ...
La monoterapia a base di pembrolizumab ha raggiunto una percentuale di risposta globale pari al 31% in pazienti affetti da carcinoma gastrico avanzato PD-L1 positivo Lo studio di Fase 2 avrà inizio nel primo trimestre del 2015 (KEYNOTE-059) MSD, nota col nome di Merck negli Stati Uniti e in Canada, ha reso nota oggi la... More...>>
09/28/20143:15AMBWMSD präsentiert erstmals Daten zum Prüfgebrauch von Pembrolizumab bei Patienten mit fortgeschrittenem Magenkrebs auf der ES...
Mit einer Pembrolizumab-Monotherapie wurde bei Patienten mit PD-L1-positivem, fortgeschrittenem Magenkrebs eine Gesamtansprechrate von 31 Prozent erzielt Phase-2-Studie soll im ersten Quartal 2015 eingeleitet werden (KEYNOTE-059) MSD, in den USA und Kanada als Merck firmierend, meldete heute die erste Präsentation von... More...>>
09/24/20149:28PMDJNCorrection to Dow Index Overseers Correction
Assets tied to the S&P 500 total about $1.9 trillion. "Correction to Dow Index Overseers Story" at 8:38 p.m. EDT misstated that assets in the S&P 500 total about $1.9 trillion. Subscribe to WSJ: http://online.wsj.com?mod=djnwires More...>>
09/24/20149:08PMDJNCorrection to Dow Index Overseers Story
Assets in the S&P 500 index total about $1.9 trillion. "Dow Index Overseers Make It Official: U.S. Firms Only" at 6:42 p.m. EDT misstated the figure as about $1.9 billion. Subscribe to WSJ: http://online.wsj.com?mod=djnwires More...>>
09/24/20147:57PMDJNDow Index Overseers Make It Official: U.S. Firms Only
By Telis Demos The keepers of the Dow Jones Industrial Average have made it clear that companies that do business in the U.S. but are incorporated overseas aren't eligible for the stock-market benchmark. The new definition will preclude companies that have moved abroad through tax-lowering inversion deals from being in... More...>>
09/24/20145:00PMBWMerck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Monday, Oct. 27. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
09/24/20146:29AMDJNGerman Data Keep European Stocks Recovery in Check -- Update
By Tommy Stubbington and Josie Cox European stocks steadied Wednesday following a two-day selloff, but yet more disappointing economic news out of Germany thwarted any kind of relief rally and underscored just how delicate the region's recovery still is. The Stoxx Europe 600 was flat in early trade having tumbled 1.4... More...>>
09/22/20145:11PMDJNMARKET SNAPSHOT: China Growth Concerns Weigh On U.S. Stocks
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks closed sharply lower on Monday, with the S&P 500 falling by its largest margin in nearly seven weeks. Investors turned skittish as they fretted about falling commodity prices and concerns about global growth. A decline in economic... More...>>
09/22/20145:07PMDJNGermany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update
By Neetha Mahadevan And Joseph Walker FRANKFURT--German pharmaceutical company Merck KGaA is paying $17 billion to acquire Sigma-Aldrich Corp., a U.S. supplier of laboratory testing materials, as Merck looks to reduce its reliance on finding blockbuster drugs. Merck will acquire all of Sigma-Aldrich for $140 a share in... More...>>
09/22/20144:24PMDJNMARKET SNAPSHOT: China Growth Concerns Weigh On U.S. Stocks
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks closed sharply lower on Monday, with the S&P 500 falling by its largest margin in nearly seven weeks. Investors turned skittish as they fretted about falling commodity prices and concerns about global growth. A decline in economic... More...>>
09/22/20144:21PMDJNMARKET SNAPSHOT: China Growth Concerns Weigh On U.S. Stocks
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks closed sharply lower on Monday, with the S&P 500 falling by its largest margin in nearly seven weeks. Investors turned skittish as they fretted about falling commodity prices and concerns about global growth. Treasurys rose... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk141001 08:21